Hideko Isozaki Received IASLC 2025 Early Career Grant
International Association for the Study of Lung Cancer (IASLC) shared on LinkedIn:
“Congrats to Dr. Hideko Isozaki, Professor in Devision of Genome Biology at Kanazawa University Cancer Research Institute! One of our 2025 Early Career Grant Awardees!
Their project, Targeting APOBEC3A as a New Therapy to Prevent Acquired Resistance Targeted Therapy in Non-Small Cell Lung Cancer, reveals that targeted therapy induces APOBEC3A expression in DTPs, promoting their genomic evolution and facilitating resistance. Over 70% of NSCLC tumors treated with TKIs exhibit high APOBEC-associated mutational signatures, highlighting the clinical relevance of this pathway. Crucially, genetic ablation of APOBEC3A preserves genomic stability in DTPs and delays the onset of resistance, supporting its potential as a therapeutic target.
We’re excited to see where this research leads, way to go, Dr. Isozaki!”
More posts featuring IASLC on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023